Spero Therapeutics (NASDAQ:SPRO) Shares Cross Above 50-Day Moving Average – Should You Sell?

Spero Therapeutics, Inc. (NASDAQ:SPRO) crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $2.42 and traded as high as $2.80. Spero Therapeutics shares last traded at $2.64, with a volume of 694,473 shares trading hands.

Analyst Ratings Changes

A number of research firms have commented on SPRO. Weiss Ratings reiterated a “sell (d-)” rating on shares of Spero Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen upgraded shares of Spero Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Sunday, March 29th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce”.

Spero Therapeutics Price Performance

The company has a fifty day moving average price of $2.44 and a 200 day moving average price of $2.37. The company has a market capitalization of $159.20 million, a P/E ratio of 22.92 and a beta of 1.45.

Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings results on Thursday, March 26th. The company reported $0.53 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.73. The business had revenue of $41.30 million for the quarter, compared to analysts’ expectations of $26.00 million. Spero Therapeutics had a return on equity of 22.53% and a net margin of 12.83%. On average, equities research analysts predict that Spero Therapeutics, Inc. will post -1.2 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Esther Rajavelu sold 87,917 shares of the company’s stock in a transaction on Friday, February 6th. The stock was sold at an average price of $2.36, for a total transaction of $207,484.12. Following the completion of the transaction, the insider directly owned 1,012,091 shares in the company, valued at $2,388,534.76. This represents a 7.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.50% of the stock is currently owned by insiders.

Institutional Trading of Spero Therapeutics

Several hedge funds have recently bought and sold shares of SPRO. GSK plc bought a new stake in Spero Therapeutics in the 4th quarter valued at about $21,414,000. Arrowstreet Capital Limited Partnership bought a new stake in Spero Therapeutics in the 3rd quarter valued at about $283,000. OMERS ADMINISTRATION Corp bought a new stake in Spero Therapeutics in the 4th quarter valued at about $306,000. Squarepoint Ops LLC bought a new stake in Spero Therapeutics in the 4th quarter valued at about $278,000. Finally, GSA Capital Partners LLP bought a new stake in Spero Therapeutics in the 3rd quarter valued at about $201,000. 25.60% of the stock is currently owned by institutional investors.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.